• 한국발생생물학회지:발생과생식
• /
• 제11권1호
• /
• pp.49-54
• /
• 2007

Ethane 1,2-dimethane sulfonate(EDS)은 Leydig cells(LC)만을 선별적 사멸을 유도하는 약물로서 가역적인 테스토스테론(testosterone, T) 결핍 흰쥐 모델을 만드는데 널리 사용된다. 본 연구에서는 수컷 흰쥐 뇌하수체의 생식소자극호르몬인 LH와 FSH의 발현에 미치는 EDS 투여 효과를 조사하였다. 성숙한 수컷 흰쥐(SD strain, $300{\sim}350\;g$ B.W.)에 EDS(75 mg/kg, i.p.)를 1회 복강주사하고 주사 후 0, 1, 2, 3, 4, 5, 6 그리고 7주가 경과한 날 희생시켰다. 뇌하수체로부터 total RNA를 추출한 후 뇌하수체 glycoprotein hormone common alpha subunit($C{\alpha}$), LH beta subunit($LH{\beta}$), FSH beta subunit($FSH{\beta}$) 그리고 GnRH 수용체(GnRH-R)의 발현 변화를 semi-quantitative RT-PCR로 측정하였다. 그 결과, $C{\alpha}$ 전사수준은 주사 후 1주부터 급격히 상승하여 주사 후 4주까지 유의하게 높게 유지되다가 5주 후부터 control 수준으로 회귀하였다. $LH{\beta}$ 전사 수준은 주사 후 2주부터 유의하게 상승하여 주사 후 4주에 최고 수준에 도달하였으며, 5주 후부터 control 수준으로 감소하였다. $FSH{\beta}$ 전사수준은 주사 후 2주부터 유의하게 상승하여 주사 후 3주에 최고 수준에 도달하였으며, 4주 후부터 감소하여 5주 후에 최소치를 보였다. 유사하게, GnRH-R 전사 수준도 주사 후 2주부터 유의하게 상승하여 주사 후 3주에 최고 수준에 도달하였으며, 5주 후부터 control 수준으로 감소하였다. 본 연구는 EDS 주사에 의해 수컷 흰쥐 뇌하수체 전엽에서의 생식소 자극호르몬 subunit들과 GnRH-R의 발현 변화가 가역적으로 유도될 수 있음을 보여준 것이다. EDS 주사 모델은 수컷 흰쥐에서의 시상하부-뇌하수체 신경내분비 축의 호르몬 조절에 대한 기작을 이해하는데 도움이 될 것이다.

• Asian-Australasian Journal of Animal Sciences
• /
• 제26권4호
• /
• pp.488-500
• /
• 2013

The objective of this study was to compare the effectiveness of the protocols for superstimulation of follicular growth in Thai native heifers. Heifers (n = 20) were randomly divided into four groups of five heifers/group. Heifers were given a single dose by i.m. administration of 100 mg Follicle Stimulating Hormone dissolved in polyvinylpyrrolidone (FSHp) at 24 h. Ovum pick up (OPU) occurred at 72 h ($F_{24}O_{72}$ protocol; Group 1) or 96 h ($F_{24}O_{96}$ protocol; Group 2), and at 36 h and OPU at 72 h ($F_{36}O_{72}$ protocol; Group 3) or 96 h ($F_{36}O_{96}$ protocol; Group 4) after follicular ablation. The dynamics of ovarian follicular growth were monitored by twice-daily ultrasonographic examinations. Blood sample collections were performed every 12 h after initiation of treatment for assessment of FSH, E2 and P4 profiles. All heifers were subjected to eight repeated sequential sessions of OPU. The follicular deviation commenced $24{\pm}5.32$ h after follicular ablation in all groups. The circulatory FSH surged quickly from 24 to 36 h (>0.8 ng/ml) after follicular ablation and circulatory estrogen levels steadily increased from 36 h until OPU in all groups. At the end of the OPU sessions, the mean number of aspirated follicles/heifer/session in $F_{36}O_{72}$ protocol (Group 3) and $F_{36}O_{96}$ protocol (Group 4) were higher than in the two other groups (p<0.05). The number of cumulus-oocyte complexes (COCs), cleaved and day 8 blastocysts rates in the $F_{36}O_{72}$ protocol (Group 3) were higher than in the other groups (p<0.05). It can be concluded that a single dose i.m. administration of 100 mg FSHp at 36 h and OPU at 72 h after follicular ablation ($F_{36}O_{72}$ protocol; Group 3) was the most effective protocol for superstimulation of follicular growth for repeated OPU and subsequent in vitro embryo production in Thai native heifers.

• Clinical and Experimental Reproductive Medicine
• /
• 제39권1호
• /
• pp.22-27
• /
• 2012

Objective: To evaluate the effectiveness of GnRH antagonist multiple dose protocol applied during early and late follicular phase (MDP-EL) in comparison with standard GnRH agonist luteal long protocol (LP) in each non-obese and obese polycystic ovary syndrome (PCOS) women undergoing IVF. Methods: Two hundred eleven infertile women with PCOS were recruited and randomized to undergo either GnRH antagonist MDP-EL (antagonist group) or standard GnRH agonist luteal LP (agonist group). IVF cycle outcomes were compared between the two groups. Results: Total dose and days of recombinant human follicle stimulating hormone (rhFSH) administered were significantly fewer in the antagonist group than in the agonist group. Incidence of severe ovarian hyperstimulation syndrome was significantly lower in the antagonist group. However, IVF and pregnancy outcomes were similar in the two groups. When all subjects were divided into non-obese and obese subgroups, in non-obese PCOS subgroup, IVF and pregnancy outcomes were comparable in the antagonist and agonist groups but total dose and days of rhFSH were also significantly fewer in the antagonist group. Similar findings were also observed in obese PCOS subgroup. Conclusion: GnRH antagonist MDP-EL is at least as effective as GnRH agonist LP and may be a more patient-friendly alternative in controlled ovarian stimulation for PCOS patients undergoing IVF, independent of body mass index.

• Clinical and Experimental Reproductive Medicine
• /
• 제40권2호
• /
• pp.83-89
• /
• 2013

Objective: To investigate outcomes of stimulated IVF cycles in which GnRH antagonist was omitted on the ovulation triggering day. Methods: A total of 86 women who underwent controlled ovarian hyperstimulation with recombinant FSH and GnRH antagonist flexible multiple-dose protocols were recruited and prospectively randomized into the conventional group (group A) or cessation group (group B). The GnRH antagonist, 0.25 mg/day of cetrorelix, was started when the leading follicle reached 14 mm in diameter and was continuously administered until the hCG triggering day (group A, 43 cycles) or until the day before hCG administration (group B, 43 cycles). The maturity of oocytes, fertilization rate, embryo quality, and implantation and clinical pregnancy rates were evaluated. Results: The duration of ovarian stimulation, total dose of gonadotropins, serum estradiol levels on hCG administration day, and number of oocytes retrieved were not significantly different between the two groups. The total dose of GnRH antagonist was significantly lower in group B than group A ($2.5{\pm}0.9$ vs. $3.2{\pm}0.8$ ampoules, p<0.05). There was no premature luteinization in any of the subjects. The proportion of mature oocytes and fertilization rate were not significantly different in group B than group A (70.7% vs. 66.7%; 71.1% vs. 66.4%, respectively). There were no significant differences in the implantation or clinical pregnancy rates. Conclusion: Our prospective randomized study suggested that cessation of GnRH antagonist on the hCG administration day during a flexible multiple-dose protocol could reduce the total dose of GnRH antagonist without compromising its effects on pregnancy rates.

• Clinical and Experimental Reproductive Medicine
• /
• 제31권4호
• /
• pp.225-234
• /
• 2004

Objectives: To evaluate the efficacy of GnRH antagonist cetrorelix in women undergoing controlled ovarian hyperstimulation (COH) for in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) and to determine changes in serum hormone concentrations during cetrorelix administration. Methods: We performed a clinical trial on 30 patients undergoing COH with highly purified follicular stimulating hormone (HP-FSH) and gonadotropin releasing hormone antagonist (GnRHant), cetrorelix. FSH was administrated from day 2 or 3 of cycle with fixed dose and adjusted according to individual response. 0.25 mg of cetrorelix was injected daily subcutaneously from stimulation day 5 until the day of hCG administration. Daily ultrasound monitoring was performed for growing follicles and serum levels of luteinizing hormone (LH), estradiol ($E_2$) and progesterone were measured daily during cetrorelix administration. Up to 4 embryos were transferred. Results: Mean age of enrolled patients was $32.0{\pm}3.4$ years (mean $\pm$ S.D.). All of 30 patients underwent oocyte pick-up, and embryo transfer was done in 28 patients. The total and mean numbers of received oocytes were 196 and $6.5{\pm}4.7$, the number of fertilized eggs was 111, and the fertilization rate was 56.6%. Total duration of FSH administration was $9.2{\pm}2.2$ days and mean of $24.3{\pm}7.7$ ampules of HP-FSH was administered. Total duration of cetrorelix administration was $5.7{\pm}1.9$ days. Serum LH and progesterone levels were maintained in the range of $1.4{\sim}2.9\;mIU/mL$ and $0.3{\sim}0.6\;ng/mL$, which respectively reflected effective prevention of premature LH surge. Clinical pregnancies were achieved in 9 patients, and overall clinical pregnancy rate was 30.0% per oocyte retrieval, and 32.1% per embryo transfer. Conclusion: GnRH antagonist is safe and convenient for COH for IVF-ET and effective with optimal pregnancy rate.

• 한국수정란이식학회지
• /
• 제20권3호
• /
• pp.311-315
• /
• 2005

본 연구는 한우를 공란우로 이용시 효율을 최대화하고, 과도한 호르몬의 투여를 억제하며, 그로 인하여 공란우의 경제수명을 연장하고자 과배란 처리시 차기 발정을 고려하지 않고 과배란을 유도하였을때 공란우의 반응과 수정란의 생산율을 조사하였으며, 그 결과는 다음과 같다. 1. 한우 경산우 및 미경산우를 자연발정을 확인하고 차기발정 5일전에 FSH를 1일 2회 4일 간 투여한 것과 발정을 확인하지 않고 CIDR를 이용하여 동일한 호르몬을 방법으로 과배란을 처리하였을 때, 반응율은 각각 $82.2\%,\;89.7\%$였으며, 유의적인 차이는 인정되지 않았다. 2. 한우 경산우 및 미경산우를 자연발정을 확인하고 차기 발정 5일전에 FSH를 1일 2회 4일간 투여한 것과 발정을 확인하지 않고 CIDR를 이용하여 동일한 호르몬을 같은 방법으로 과배란을 처리하였을 때, 수정란의 회수율은 각각 7.7개, 10.5개를 회수하였고, 그 중 이식가능 수정란은 각각 3.4개, 3.8개를 나타냈으며, 두 처리간에 유의적인 차이를 나타냈다(p<0.05). 이상의 결과로 한우 공란우는 경산우 및 미경산우를 발정주기를 확인하지 않고도 과배란처리시 반응을 확인할 수 있었으며, 수정란의 회수에 있어서도 적절하게 채취할 수 있으므로 한우를 공란우로서 과도한 호르몬으로부터 보호할 수 있으며, 그에 따라 경제수명을 연장할 수 있을 것으로 사료된다. 또한 고능력 한우를 이용한 수정란 이식의 활성화에 유용한 방법이며, 농가에도 확산하여 소득향상에 기여할 수 있을 것으로 기대된다.

• 한국발생생물학회지:발생과생식
• /
• 제13권4호
• /
• pp.329-339
• /
• 2009

Cortisol은 난소내 다량으로 존재하며, 난소 세포에 그 수용체가 있는 것으로 보고되고 있다. 또한 사람의 과립 및 황체화 세포에서 cortisol은 스테로이드 생성과 세포 대사에 영향을 미치는 것으로 알려지고 있으나, 배란 후 난포액에 높은 농도로 존재하는 cortisol이 과립-황체화 세포에 어떤 영향을 미치는 지는 정확히 밝혀져 있지 않다. 따라서 본 실험에서 과배란 유도후 획득한 사람 과립-황체화 세포를 배양하면서 5, 50, $500{\mu}g/m\ell$ cortisol과 1 IU/$m\ell$ FSH를 처리하고 세포의 세포자연사와 분비된 progesterone$(P_4)$과 estradiol$(E_2)$량의 변화를 조사하였다. DNA 분절화 분석과 TUNEL 방법으로 세포자연사를 평가한 결과, cortisol는 농도 의존적으로 과립-황체화 세포의 세포자연사를 증가시켰고, 특히 50과 $500{\mu}g/m\ell$ cortisol을 처리한 군에서 유의한 차이를 보이며 세포자연사 비율을 증가시켰다. 또한 cortisol에 의한 세포자연사의 증가는 FSH에 의해 억제되지 못함을 알 수 있었다. 화학발광면역 측정법을 이용하여 배양내 $P_4$와 $E_2$의 양을 측정한 결과, cortisol을 처리한 후 $E_2$의 양은 변화가 없었던 반면 $P_4$의 양은 감소하였다. 이러한 cortisol의 $P_4$ 합성 억제 효과는 세포자연사 결과와 마찬가지로 FSH에 의해 회복되지 못함을 확인할 수 있었다. 이상의 결과는 일정 농도 이상의 cortisol은 과립-황체화 세포의 세포자연사를 유발시킬 수 있으며, 또한 $P_4$의 합성을 억제시킴으로써 난포 폐쇄를 직접적으로 유발시킬 수 있음 보여준다. 그러나 본 연구 결과들은 기존의 연구 결과와 상반된 결과를 보이고 있으며, 앞으로 과립-황체화 세포에 대한 cortisol의 생리적인 관련성을 밝혀 그 기전을 명확히 할 필요성이 있다.

• 한국수정란이식학회지
• /
• 제27권3호
• /
• pp.127-131
• /
• 2012

발정주기와 상관없이 CIDR을 삽입하는 날에 50 mg progesterone, 2.5 mg estradiol benzoate를 근육주사하였다. CIDR 삽입 후 4, 5일에 28 AU FSH (Antorin R10)을 4일 동안 감량법으로 주사하였다. 6, 7회 FSH 주사 후 25 mg, 15 mg $PGF_2{\alpha}$를 각각 주사한 다음, CIDR는 7회 FSH 주사 후 제거하였다. 1회째 $PGF_2{\alpha}$ 주사 후 48시간에 $200{\mu}g$ GnRH를 주사하였다. 공란우는 발정확인 후 12시간 간격으로 3회 인공수정을 실시하였으며, 수정란의 채란은 발정확인 후 7일째 회수하였다. 과배란 처리된 공란우에서 회수된 총 난자수, 이식가능 수정란, 퇴행란 및 미수정란은 각각 $11.6{\pm}7.9$, $5.5{\pm}4.4$, $3.0{\pm}3.3$ 및 $2.6{\pm}4.1$개였다. 1~2산의 공란우($8.9{\pm}1.9$)보다 3~5산의 공란우($14.3{\pm}1.3$)에서 총 난자수가 유의적으로 많았다(P<0.05). 회수된 정상 수정란 수도 3~5산의 공란우($7.3{\pm}0.8$)에서 6산 이상의 공란우($3.7{\pm}1.5$)보다 유의적으로 많았다(P<0.05). 회수된 총 난자수와 정상수정란도 각각 가을($10.1{\pm}1.8$, $4.5{\pm}1.1$)과 겨울($6.3{\pm}1.8$, $3.3{\pm}1.1$)보다 여름($16.4{\pm}2.3$, $8.1{\pm}1.4$)에 유의적으로 많았다(P<0.05). 이식가능 수정란은 겨울($3.0{\pm}1.0$)보다 여름($7.6{\pm}1.3$)에서 유의적으로 많이 회수하였다(P<0.05). 결론적으로 공란우의 산차, 과배란 처리계절은 한우수정란 생산에 영향을 미치는 것으로 나타났다.

• The Korean Journal of Physiology and Pharmacology
• /
• 제27권2호
• /
• pp.167-176
• /
• 2023

This study aims to explore the impact of Rehmannioside D (RD) on ovarian functions of rats with diminished ovarian reserve (DOR) and its underlying mechanisms of action. A single injection of cyclophosphamide was performed to establish a DOR rat model, and fourteen days after the injection, the rats were intragastrically administrated with RD for two weeks. Rat estrus cycles were tested using vaginal smears. Ovarian tissues were histologically evaluated, the number of primordial, mature, and atretic follicles was calculated, and the apoptotic rate of granulosa cells. Follicle-stimulating hormone (FSH), luteinizing hormone (LH), and estradiol (E₂) levels were determined by ELISA assays. Protein levels of Forkhead Box O1 (FOXO1), KLOTHO, Bcl-2, and Bax were investigated in ovarian tissues of DOR rats. The binding between FOXO1 and KLOTHO was verified by ChIP assay. High-dose administration of RD into DOR rats improved their estrus cycles, increased ovarian index, enhanced the number of primordial and mature follicles, reduced the number of atretic follicle number, and ovarian granulosa cell apoptosis in addition to inhibiting FSH and LH levels and upregulating E₂ expression. FOXO1 and KLOTHO were significantly suppressed in DOR rats. FOXO1 knockdown partially suppressed the protective effects of RD on DOR rats, and KLOTHO overexpression could restore RD-induced blockade of DOR development despite knocking down FOXO1. FOXO1 antibody enriched KLOTHO promoter, and the binding between them was reduced in DOR group compared to that in sham group. RD improved ovarian functions in DOR rats and diminished granulosa cell apoptosis via the FOXO1/KLOTHO axis.

• Fisheries and Aquatic Sciences
• /
• 제14권4호
• /
• pp.379-388
• /
• 2011

The mechanism by which gonadotropin-releasing hormone (GnRH) and dopamine (DA) control gonadotropin (GTH) release was studied in male and female rainbow trout using cultured pituitary cells obtained at different reproductive stages. The mechanisms of follicle-stimulating hormone (FSH) release by GnRH and DA could not be determined yet. However, basal and salmon-type GnRH (sGnRH)- or chicken-II-type GnRH (cGnRH-II)- induced luteinizing hormone (LH) release increased with gonadal maturation in both sexes. LH release activity was higher after sGnRH stimulation than cGnRH-II stimulation at maturing stages in both sexes. The GnRH antagonist ([Ac-3, 4-dehydro-$Pro^1$, D-p-F-$Phe^2$, D-$Trp^{3,6}$] GnRH) suppressed LH release by sGnRH stimulation in a dose-dependent manner, although the effect was weak in maturing fish. The role of DA as a GTH-release inhibitory factor differs during the reproductive cycle: the inhibition of sGnRH-stimulated LH release by DA was stronger in immature fish than in maturing, ovulating, or spermiated fish. DA did not completely inhibit sGnRH-stimulated LH release, and DA alone did not alter basal LH release. Relatively high doses ($10^{-6}$ or $10^{-5}M$) of domperidone (DOM, a DA D2 antagonist) increased LH release, which did not change with reproductive stage in either sex. The potency of DOM to enhance sGnRH-stimulated LH release was higher in maturing and ovulated fish than in immature fish. These data suggest that LH release from the pituitary gland is controlled by dual neuroendocrine mechanisms by GnRH and DA in rainbow trout, as has been reported in other teleosts. The mechanism of control of FSH release, however, remains unknown.